RxDoctor Payments Data

Tej-Preet Singh, MD

Neurology · Massapequa, NYNPI 1194798280

Payments from drug & device makers

$14,186in general payments, 2019–2025

Across 727 payments — averaging $19.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Keystone Dental Inc.$1K
  • UCB, Inc.$760
  • Biogen$721
  • Eisai Inc.$709
  • Avanir Pharmaceuticals, Inc.$544
  • plus $8K from 54 others

What the payments were for

  • Speaking & faculty fees$1601%
  • Food & beverage$12,50188%
  • Education$1111%
  • Entertainment$1,41310%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)120$1,925
Keystone Dental Inc.17$1,444
UCB, Inc.47$760
Biogen45$721
Eisai Inc.21$709
Avanir Pharmaceuticals, Inc.25$544
Teva Pharmaceuticals USA, Inc.18$539
Lundbeck LLC29$506
Novartis28$463
Amneal Pharmaceuticals LLC22$413
AstraZeneca21$392
Takeda Pharmaceuticals U.S.A., Inc.19$378
Arbor Pharmaceuticals, Inc.21$337
Ipsen Biopharmaceuticals, Inc18$308
Pfizer14$283
Supernus Pharmaceuticals, Inc.17$279
Upsher-smith Laboratories LLC13$251
Amgen(2 entities)14$228
Lilly USA, LLC14$218
Sanofi14$215
EMD Serono, Inc.13$195
Argenx US, Inc.9$189
Biohaven Pharmaceuticals, Inc.10$179
Sunovion Pharmaceuticals Inc.12$178
Acorda Therapeutics, Inc9$160
Biohaven Pharmaceutical Holding Company Ltd.8$157
Neurelis, Inc.8$146
Redhill Biopharma Inc.7$126
Scilex Pharmaceuticals Inc.7$125
Collegium Pharmaceutical, Inc.7$112
GE HealthCare8$106
Sumitomo Pharma America, Inc.5$95
Grifols USA, LLC4$88
Kyowa Kirin, Inc.5$88
Impel Pharmaceuticals Inc.4$80
Almatica Pharma LLC4$76
Bristol Myers Squibb4$71
Bausch Health US, LLC4$69
SK Life Science, Inc.4$64
Tris Pharma Inc3$62
Acadia Pharmaceuticals Inc4$58
Corium, LLC3$51
E.r. Squibb & Sons, L.L.C.3$48
Harmony Biosciences LLC3$48
Otsuka America Pharmaceutical, Inc.3$44
Abbott2$43
Axsome Therapeutics, Inc.2$39
Shire North American Group Inc2$39
Biodelivery Sciences International, Inc.2$35
Merz Pharmaceuticals, LLC2$34
Amylyx Pharmaceuticals, Inc.2$32
Catalyst Pharmaceuticals, Inc.2$32
Neos Therapeutics, LP2$32
Tanabe Pharma America, Inc.2$32
Promius Pharma LLC2$28
Sentynl Therapeutics, Inc.2$26
Adlon Therapeutics L.p.1$24
Merck1$24
Mallinckrodt Enterprises LLC1$23
ANI Pharmaceuticals, Inc.1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,186 in reported general payments places this provider in the 70th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$417,084
Medicare patients
462
Services billed
15,046

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5013$386,359
OxycontinOxycodone Hcl45$85,646
NuedextaDextromethorphan Hbr/Quinidine24$76,908
NamzaricMemantine Hcl/Donepezil Hcl63$74,448
Nurtec OdtRimegepant Sulfate39$68,863
Oxtellar XrOxcarbazepine13$28,340
Nucynta ErTapentadol Hcl15$23,561
NeuproRotigotine15$17,815
RytaryCarbidopa/Levodopa11$12,458
Xtampza ErOxycodone Myristate11$12,105
Trokendi XrTopiramate12$10,859
Topiramate ErTopiramate12$9,204
Aimovig AutoinjectorErenumab-Aooe11$7,758
Memantine Hcl ErMemantine Hcl43$7,600
Hydromorphone ErHydromorphone Hcl11$6,965

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Nurtec Odt, Dilantin$283$458,93666 claims
Avanir Pharmaceuticals, Inc.Nuedexta$544$76,90824 claims
AbbVieNamzaric$1,925$74,44863 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr, Trokendi Xr$279$39,20025 claims
Collegium Pharmaceutical, Inc.Nucynta Er, Xtampza Er$112$35,66626 claims
UCB, Inc.Neupro$760$17,81515 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$413$13,22926 claims
Almatica Pharma LLCSertraline Hcl$76$68358 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,623 neurology providers in New York.

Other neurology in Massapequa

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →